Related Experiment Videos
[Clinical studies on imipenem/cilastatin sodium in perinatal use]
T Chimura1, N Morisaki, T Hirayama
1Department of Obstetrics and Gynecology, School of Medicine, Yamagata University.
Insights
Imipenem/cilastatin sodium (IPM/CS) demonstrated 100% clinical efficacy in treating perinatal infections, with no observed side effects. This antibiotic combination proved effective even in patients unresponsive to prior treatments.
Area of Science:
- Obstetrics and Gynecology
- Infectious Diseases
- Pharmacology
Background:
- Perinatal infections pose significant risks to maternal and infant health.
- Evaluating novel antimicrobial agents is crucial for improving treatment outcomes.
- Imipenem/cilastatin sodium (IPM/CS) is a broad-spectrum antibiotic combination.
Observation:
- A study assessed the clinical efficacy and safety of intravenous imipenem/cilastatin sodium (IPM/CS) in 22 patients with perinatal infections.
- Patients included those with endometritis, amniotic fluid infections, puerperal fever, and other related infections.
- Treatment involved intravenous drip infusion of IPM/CS, with dosages ranging from 0.5g to 1.0g of imipenem (IPM).
Findings:
- 100% clinical efficacy was observed, with 20% excellent and 80% good responses.
- IPM/CS was effective in 10 patients who had not responded to previous antibiotic therapies.
- Bacterial eradication was achieved in 4 patients, with decreases or replacement in others.
- No adverse side effects or abnormal clinical laboratory test values were reported.
Implications:
- Imipenem/cilastatin sodium (IPM/CS) presents a safe and highly effective treatment option for various perinatal infections.
- Its efficacy in refractory cases highlights its potential as a first-line agent.
- Further research may explore its role in managing antibiotic-resistant pathogens in obstetric settings.
Abstract:
The clinical efficacy and the safety of imipenem/cilastatin sodium (IPM/CS) in perinatal infections were studied. The results are summarized below. 1. Clinical efficacy was evaluated in 12 patients with intrauterine infections (endometritis), 3 patients with amniotic fluid infections, 2 patients with puerperal fever and 3 patients with other infections. The drug was administered by intravenous drip infusion at a 0.5g to 1.0g dose as IPM and the total doses during an entire course of treatment were 1.5g to 15g. 2. Clinical efficacies were excellent in 4 (20%) and good in 16 patients (80%) and the efficacy rate was 100%. Ten patients had not improved upon treatments with other previous antibiotics. 3. Infective bacteria were eradicated in 4, decreased in 1, and replaced in 6 patients. 4. No side effects or abnormal clinical laboratory test values were observed in any patient.